(NASDAQ: SGMT) Sagimet Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.49%.
Sagimet Biosciences's earnings in 2026 is -$57,671,000.On average, 12 Wall Street analysts forecast SGMT's earnings for 2026 to be -$63,846,403, with the lowest SGMT earnings forecast at -$70,435,279, and the highest SGMT earnings forecast at -$56,343,670. On average, 10 Wall Street analysts forecast SGMT's earnings for 2027 to be -$67,518,092, with the lowest SGMT earnings forecast at -$94,338,654, and the highest SGMT earnings forecast at -$42,105,714.
In 2028, SGMT is forecast to generate -$74,305,349 in earnings, with the lowest earnings forecast at -$105,174,851 and the highest earnings forecast at -$56,685,147.